Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Lomonitinib |
| Synonyms | |
| Therapy Description |
Lomonitinib (ZE46-0134) is an inhibitor of FLT3 and IRAK4, with activity against FLT3-ITD mutations and FLT3 F691L, which reduces downstream signaling and potentially inhibits tumor cell proliferation (Blood (2024) 144 (Supplement 1): 1396, NCI Drug Dictionary). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Lomonitinib | ZE46 0134|ZE46-0134|ZE46 0134 | FLT3 Inhibitor 69 IRAK4 Inhibitor 8 | Lomonitinib (ZE46-0134) is an inhibitor of FLT3 and IRAK4, with activity against FLT3-ITD mutations and FLT3 F691L, which reduces downstream signaling and potentially inhibits tumor cell proliferation (Blood (2024) 144 (Supplement 1): 1396, NCI Drug Dictionary). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06366789 | Phase I | Lomonitinib | Dose Escalation and Expansion Study to Evaluate the Safety, PK, PD and Efficacy of ZE46-0134 in Adults With FLT3 Mutated Relapsed or Refractory Acute Myeloid Leukemia | Recruiting | AUS | 0 |